Linagliptin prevents left ventricular stiffening by reducing titin cleavage and hypophosphorylation.
Autor: | Cuijpers I; Center for Molecular and Vascular Biology, KU Leuven, Leuven, Belgium.; Department of Cardiology, CARIM School for Cardiovascular Diseases, Maastricht University Medical Center, Maastricht, The Netherlands., Papageorgiou AP; Center for Molecular and Vascular Biology, KU Leuven, Leuven, Belgium.; Department of Cardiology, CARIM School for Cardiovascular Diseases, Maastricht University Medical Center, Maastricht, The Netherlands., Carai P; Center for Molecular and Vascular Biology, KU Leuven, Leuven, Belgium., Herwig M; Molecular Cardiology and Experimental Cardiology, Ruhr University Bochum, Bochum, Germany.; Department of Cardiology, St. Josef-Hospital, Ruhr University Bochum, Bochum, Germany.; Institute of Physiology, Ruhr University Bochum, Bochum, Germany., Mügge A; Molecular Cardiology and Experimental Cardiology, Ruhr University Bochum, Bochum, Germany.; Department of Cardiology, St. Josef-Hospital, Ruhr University Bochum, Bochum, Germany., Klein T; Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany., Hamdani N; Molecular Cardiology and Experimental Cardiology, Ruhr University Bochum, Bochum, Germany.; Department of Cardiology, St. Josef-Hospital, Ruhr University Bochum, Bochum, Germany.; Institute of Physiology, Ruhr University Bochum, Bochum, Germany.; Department of Clinical Pharmacology, Ruhr University Bochum, Bochum, Germany., Jones EAV; Center for Molecular and Vascular Biology, KU Leuven, Leuven, Belgium.; Department of Cardiology, CARIM School for Cardiovascular Diseases, Maastricht University Medical Center, Maastricht, The Netherlands., Heymans S; Center for Molecular and Vascular Biology, KU Leuven, Leuven, Belgium.; Department of Cardiology, CARIM School for Cardiovascular Diseases, Maastricht University Medical Center, Maastricht, The Netherlands.; Holland Heart House, ICIN-Netherlands Heart Institute, Utrecht, The Netherlands. |
---|---|
Jazyk: | angličtina |
Zdroj: | Journal of cellular and molecular medicine [J Cell Mol Med] 2021 Jan; Vol. 25 (2), pp. 729-741. Date of Electronic Publication: 2020 Dec 09. |
DOI: | 10.1111/jcmm.16122 |
Abstrakt: | The metabolic syndrome (MetS) is an escalating problem worldwide, causing left ventricular stiffening, an early characteristic of diastolic dysfunction for which no treatment exists. As diastolic dysfunction and stiffening in MetS patients are associated with increased circulating dipeptidyl peptidase-4 (DPP-4) levels, we investigated whether the clinically approved DPP-4 inhibitor linagliptin reduces left ventricular stiffness in MetS-induced cardiac disease. Sixteen-week-old obese ZSF1 rats, displaying the MetS and left ventricular stiffness, received linagliptin-supplemented or placebo diet for four weeks. Linagliptin significantly reduced obesity, hyperlipidaemia, and hyperglycaemia and improved left ventricular relaxation. This improved relaxation was related to decreased cardiac fibrosis and cardiomyocyte passive stiffness (F (© 2020 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.) |
Databáze: | MEDLINE |
Externí odkaz: |